Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Massimo Mascolo is active.

Publication


Featured researches published by Massimo Mascolo.


Journal of The American Academy of Dermatology | 2012

Accuracy in melanoma detection: A 10-year multicenter survey

Giuseppe Argenziano; Lorenzo Cerroni; Iris Zalaudek; Stefania Staibano; Rainer Hofmann-Wellenhof; Nicola Arpaia; Renato Marchiori Bakos; B. Balme; Jadran Bandic; Roberto Bandelloni; Alexandra Maria Giovanna Brunasso; Horacio Cabo; David A. Calcara; Blanca Carlos-Ortega; Ana Carolina Carvalho; Gabriel Casas; Huiting Dong; Gerardo Ferrara; Raffaele Filotico; Guillermo Gómez; Allan C. Halpern; Gennaro Ilardi; Akira Ishiko; Gulsen Kandiloglu; Hiroshi Kawasaki; Ken Kobayashi; Hiroshi Koga; Ivanka Kovalyshyn; David Langford; Xin Liu

BACKGROUND Early excision is the only strategy to reduce melanoma mortality, but unnecessary excision of benign lesions increases morbidity and healthcare costs. OBJECTIVE To assess accuracy in melanoma detection based on number-needed-to-excise (NNE) values over a 10-year period. METHODS Information was retrieved on all histopathologically confirmed cutaneous melanomas or melanocytic nevi that were excised between 1998 and 2007 at participating clinics. NNE values were calculated by dividing the total number of excised lesions by the number of melanomas. Analyses included changes in NNE over time, differences in NNE between specialized clinical settings (SCS) versus non-specialized clinical settings (NSCS), and patient factors influencing NNE. RESULTS The participating clinics contributed a total of 300,215 cases, including 17,172 melanomas and 283,043 melanocytic nevi. The overall NNE values achieved in SCS and NSCS in the 10-year period were 8.7 and 29.4, respectively. The NNE improved over time in SCS (from 12.8 to 6.8), but appeared unchanged in NSCS. Most of the effect on NNE in SCS was due to a greater number of excised melanomas. Higher NNE values were observed in patients younger than 40 years and for lesions located on the trunk. LIMITATIONS No data concerning the use of dermatoscopy and digital monitoring procedures were collected from the participating centers. CONCLUSION Over the 10-year study period, accuracy in melanoma detection improved only in specialized clinics maybe because of a larger use of new diagnostic techniques such as dermatoscopy.


Cell Death & Differentiation | 2010

Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells

Simona Romano; Anna D'Angelillo; R Pacelli; Stefania Staibano; E De Luna; Rita Bisogni; E-L Eskelinen; Massimo Mascolo; G Calì; C Arra; Maria Fiammetta Romano

FK506-binding protein 51 (FKBP51) is an immunophilin with isomerase activity, which performs important biological functions in the cell. It has recently been involved in the apoptosis resistance of malignant melanoma. The aim of this study was to investigate the possible role of FKBP51 in the control of response to ionizing radiation (Rx) in malignant melanoma. FKBP51-silenced cells showed reduced clonogenic potential after irradiation compared with non-silenced cells. After Rx, we observed apoptosis in FKBP51-silenced cells and autophagy in non-silenced cells. The FKBP51-controlled radioresistance mechanism involves NF-κB. FKBP51 was required for the activation of Rx-induced NF-κB, which in turn inhibited apoptosis by stimulating X-linked inhibitor of apoptosis protein and promoting authophagy-mediated Bax degradation. Using a tumor–xenograft mouse model, the in vivo pretreatment of tumors with FKBP51-siRNA provoked massive apoptosis after irradiation. Immunohistochemical analysis of 10 normal skin samples and 80 malignant cutaneous melanomas showed that FKBP51 is a marker of melanocyte malignancy, correlating with vertical growth phase and lesion thickness. Finally, we provide evidence that FKBP51 targeting radiosensitizes cancer stem/initiating cells. In conclusion, our study identifies a possible molecular target for radiosensitizing therapeutic strategies against malignant melanoma.


Digestive and Liver Disease | 2010

In vivo characterisation of superficial colorectal neoplastic lesions with high-resolution probe-based confocal laser endomicroscopy in combination with video-mosaicing: A feasibility study to enhance routine endoscopy

Giovanni Domenico De Palma; Stefania Staibano; Saverio Siciliano; Marcello Persico; Stefania Masone; Francesco Maione; Maria Siano; Massimo Mascolo; Dario Esposito; Francesca Salvatori; Giovanni Persico

BACKGROUND Recent technological advances in miniaturisation have allowed for a confocal scanning microscope to be integrated into trans-endoscopic probes enabling endoscopists to collect in vivo virtual biopsies of the gastrointestinal mucosa during endoscopy. AIMS The aim of the present study was to assess prospectively the clinical applicability and predictive power of a probe-based confocal laser endomicroscopy for the in vivo diagnosis of colorectal neoplasia. METHODS Patients with evidence of colorectal superficial neoplasia at routine endoscopy, were included prospectively in this study. Lesions were identified using white-light endoscopy followed by pCLE imaging recorded by a Coloflex UHD-type probe. The images were interpreted as either neoplastic or not according to vascular and cellular changes. pCLE readings were then compared with histopathological results from endoscopically resected lesions and/or targeted biopsy specimens. RESULTS A total of 32 lesions were identified in 20 consecutive patients. Histopathology diagnosis was of adenomas in 19 cases, hyperplastic polyps in 11 cases and adenocarcinoma in 2 cases. For the detection of neoplastic tissue pCLE had a sensitivity of 100%, a specificity of 84.6%, an accuracy of 92.3, a PPV of 90.5% and a NPV of 100%. CONCLUSIONS pCLE permits high-quality imaging, enabling prediction of intraepithelial neoplasia with a high level of accuracy.


International Journal of Molecular Sciences | 2012

Epigenetic Disregulation in Oral Cancer

Massimo Mascolo; Maria Siano; Gennaro Ilardi; Daniela Russo; Francesco Merolla; Gaetano De Rosa; Stefania Staibano

Squamous cell carcinoma of the oral region (OSCC) is one of the most common and highly aggressive malignancies worldwide, despite the fact that significant results have been achieved during the last decades in its detection, prevention and treatment. Although many efforts have been made to define the molecular signatures that identify the clinical outcome of oral cancers, OSCC still lacks reliable prognostic molecular markers. Scientific evidence indicates that transition from normal epithelium to pre-malignancy, and finally to oral carcinoma, depends on the accumulation of genetic and epigenetic alterations in a multistep process. Unlike genetic alterations, epigenetic changes are heritable and potentially reversible. The most common examples of such changes are DNA methylation, histone modification, and small non-coding RNAs. Although several epigenetic changes have been currently linked to OSCC initiation and progression, they have been only partially characterized. Over the last decade, it has been demonstrated that especially aberrant DNA methylation plays a critical role in oral cancer. The major goal of the present paper is to review the recent literature about the epigenetic modifications contribution in early and later phases of OSCC malignant transformation; in particular we point out the current evidence of epigenetic marks as novel markers for early diagnosis and prognosis as well as potential therapeutic targets in oral cancer.


Cell Cycle | 2010

Differential role of CD133 and CXCR4 in renal cell carcinoma

Crescenzo D'Alterio; Luca Cindolo; Luigi Portella; Marianeve Polimeno; Consales C; Anna Riccio; Cioffi M; Renato Franco; Paolo Chiodini; G. Carteni; Mirone; N. Longo; Luigi Marra; Sisto Perdonà; Luigi Claudio; Massimo Mascolo; Stefania Staibano; M. Falsaperla; Puglisi M; Martignoni G; Ficarra; Giuseppe Castello; Stefania Scala

The chemokine receptor CXCR4 and CD133, putative stem cell markers, were previously described in renal cancer (RCC). To evaluate the biological and prognostic role of CD133 and CXCR4 in RCC the expression was evaluated through qPCR and immunoblotting in human renal cancer cell lines (786-O, A498, ACHN, CAKI-1, SN12C, TK10, UO31) and patients biopsies. Renal cancer cells and surgical biopsies expressed functional CXCR4 while CD133 was not detectable. CXCR4 and CD133 expression was then evaluated in 240 renal cancer patients through immunohistochemistry. CXCR4 and CD133 were low in 19.1% and 59.6%; intermediate in 20% and 17.9%; high in 60.8% and 22.5% of the cases, respectively. CXCR4 was overexpressed in tumours (p= 0.02), while CD133 was over expressed in healthy tissues (p= 0.04). Disease free survival Kaplan Meier plots suggest that prognosis is unfavourable for patients whose primary tumours express CXCR4 (p= 0.0199) but nor CD133 (p= 0.151) neither the concomitant CXCR4-CD133 (p=0.848) high expression affected prognosis. Analysis of prognostic factors suggests that age, clinical presentation, AJCC stage and CXCR4 had a significant prognostic value at the univariate analysis. The CXCR4 predictive ability was confirmed at the multivariate analysis while no prognostic role was identified for CD133. Thus concomitant CD133 and CXCR4 evaluation is not worth in RCC patient while the CXCR4 prognostic role encourage CXCR4 antagonists as promising therapeutic option.


European Journal of Obstetrics & Gynecology and Reproductive Biology | 2009

Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: Relationship between clinical features and immunohistochemical changes

Marianna De Falco; Stefania Staibano; Massimo Mascolo; Chiara Mignogna; Luigi Improda; Francesca Ciociola; Ilma Floriana Carbone; Andrea Di Lieto

OBJECTIVE To evaluate if pre-operative GnRH-a modify uterine leiomyoma pseudocapsule and the possible clinical effects of these changes. STUDY DESIGN The study was performed at the University Federico II of Naples on 33 premenopausal patients submitted to laparotomic myomectomy after treatment with triptorelin depot. 29 untreated patients formed the control group. The operating time, the intraoperative bleeding and the prompt identification of the cleavage plan between myoma and myometrium were evaluated. The pseudocapsule features and the immunoexpression of PCNA and CD34 in this area were studied. RESULTS Treated patients showed lower blood loss and not clearly identifiable cleavage plan, but without any significant increase in the operating time. Treated lesions showed less evident border between myoma and myometrium and lower PCNA and CD34 pseudocapsule immunoexpression than untreated ones. CONCLUSION We propose the changes of leiomyoma pseudocapsule as partial explanations of the reported clinical and surgical findings after pre-operative GnRH-a.


BMC Cancer | 2006

Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: A five year follow-up analysis

Chiara Mignogna; Stefania Staibano; Vincenzo Altieri; Gaetano De Rosa; Giuseppe Pannone; Angela Santoro; Rosanna Zamparese; Massimino D'Armiento; Romualdo Rocchetti; Ernesto Mezza; Mario Nasti; Viviana Strazzullo; Vittorino Montanaro; Massimo Mascolo; Pantaleo Bufo

BackgroundA large number of renal cancer patients shows poor or partial response to chemotherapy and the mechanisms have not been still understood. Multi-drug resistance is the principal mechanism by which many cancers develop resistance to chemotherapic drugs. The role of the multi-drug resistant transporter (MDR-1/P-glycoprotein), the gene product of MDR-1, and that one of the so-called multi-drug resistance associated protein (MRP), two energy-dependent efflux pumps, are commonly known to confer drug resistance.We studied MDR-1 expression in selected cases of renal cell carcinoma (RCC), clear cell type, with long-term follow-up, in order to establish its prognostic role and its possible contribution in the choice of post-surgical therapy.MethodsMDR-1 has been studied by standard LSAB-HRP immunohistochemical technique, in paraffin embedded RCC samples. Protein expression has been compared to clinical and histopathological data and to disease specific survival of RCC patients, by Kaplan-Meier curve and Cox multivariate regression analyses.ResultsTwo groups of RCCs were obtained by esteeming MDR-1 expression and disease specific survival (obtained with Kaplan-Meier curve and Cox multivariate regression analyses): the first one presents low or absent MDR-1 expression and good survival; the second one is characterized by high MDR-1 expression and significant poor outcome (p < 0.05). Afterwards, we have found disease specific survival, adjusted for stages and independent of therapy: this difference of survival rates was statistically significant (p < 0.05). Stage adjusted disease specific survival rate, according to MDR-1 expression and therapy in patients affected by RCC in early stage (stage I), has revealed that the group of patients with high MDR-1 expression and without adjuvant therapy showed poor survival (p < 0.05). Cox multivariate regression analysis has confirmed that, in our cohort of RCC (clear cell type) patients, the strong association between MDR-1 and worse outcome is independent not only of the adjuvant therapy, but also of the other prognostic parameters (p < 0.05).ConclusionIn our opinion, the results of this study well prove the relationship between MDR-1 expression and worse clinical prognosis in RCC, because MDR-1 over-expressing RCCs can be considered a group of tumours with a more aggressive behavior. This finding outlines a possible role of MDR-1 as prognostic factor, dependent and independent of multidrug resistance. These results could be useful to predict cancer evolution and to choose the appropriate treatment: this is another step that can stimulate further promising and interesting investigations on broader study population.


Cell Death and Disease | 2013

FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential

Simona Romano; Stefania Staibano; Adelaide Greco; Arturo Brunetti; Giovanna Nappo; Gennaro Ilardi; Rosanna Martinelli; Antonio Sorrentino; A Di Pace; Massimo Mascolo; Rita Bisogni; M Scalvenzi; Bruno Alfano; Maria Fiammetta Romano

Melanoma is the most aggressive skin cancer; there is no cure in advanced stages. Identifying molecular participants in melanoma progression may provide useful diagnostic and therapeutic tools. FK506 binding protein 51 (FKBP51), an immunophilin with a relevant role in developmental stages, is highly expressed in melanoma and correlates with aggressiveness and therapy resistance. We hypothesized a role for FKBP51 in melanoma invasive behaviour. FKBP51 promoted activation of epithelial-to-mesenchymal transition (EMT) genes and improved melanoma cell migration and invasion. In addition, FKBP51 induced some melanoma stem cell (MCSC) genes. Purified MCSCs expressed high EMT genes levels, suggesting that genetic programs of EMT and MCSCs overlap. Immunohistochemistry of samples from patients showed intense FKBP51 nuclear signal and cytoplasmic positivity for the stem cell marker nestin in extravasating melanoma cells and metastatic brains. In addition, FKBP51 targeting by small interfering RNA (siRNA) prevented the massive metastatic substitution of liver and lung in a mouse model of experimental metastasis. The present study provides evidence that the genetic programs of cancer stemness and invasiveness overlap in melanoma, and that FKBP51 plays a pivotal role in sustaining such a program.


British Journal of Cancer | 2007

OPN/CD44v6 overexpression in laryngeal dysplasia and correlation with clinical outcome

S. Staibano; Francesco Merolla; Domenico Testa; Renata Iovine; Massimo Mascolo; Valentina Guarino; Maria Domenica Castellone; M Di Benedetto; Vieri Galli; S Motta; Rosa Marina Melillo; G. De Rosa; Massimo Santoro; Angela Celetti

Laryngeal dysplasia is a common clinical concern. Despite major advancements, a significant number of patients with this condition progress to invasive squamous cell carcinoma. Osteopontin (OPN) is a secreted glycoprotein, whose expression is markedly elevated in several types of cancers. We explored OPN as a candidate biomarker for laryngeal dysplasia. To this aim, we examined OPN expression in 82 cases of dysplasia and in hyperplastic and normal tissue samples. OPN expression was elevated in all severe dysplasia samples, but not hyperplastic samples, with respect to matched normal mucosa. OPN expression levels correlated positively with degree of dysplasia (P=0.0094) and negatively with disease-free survival (P<0.0001). OPN expression was paralleled by cell surface reactivity for CD44v6, an OPN functional receptor. CD44v6 expression correlated negatively with disease-free survival, as well (P=0.0007). Taken as a whole, our finding identify OPN and CD44v6 as predictive markers of recurrence or aggressiveness in laryngeal intraepithelial neoplasia, and overall, point out an important signalling complex in the evolution of laryngeal dysplasia.


Journal of Biological Chemistry | 2010

PTPD1 supports receptor stability and mitogenic signaling in bladder cancer cells

Annalisa Carlucci; Monia Porpora; Corrado Garbi; Mario Galgani; Margherita Santoriello; Massimo Mascolo; Domenico di Lorenzo; Vincenzo Altieri; Maria Quarto; Luigi Terracciano; Max E. Gottesman; Luigi Insabato; Antonio Feliciello

PTPD1, a cytosolic non-receptor protein-tyrosine phosphatase, stimulates the Src-EGF transduction pathway. Localization of PTPD1 at actin cytoskeleton and adhesion sites is required for cell scattering and migration. Here, we show that during EGF stimulation, PTPD1 is rapidly recruited to endocytic vesicles containing the EGF receptor. Endosomal localization of PTPD1 is mediated by interaction with KIF16B, an endosomal kinesin that modulates receptor recycling at the plasma membrane. Silencing of PTPD1 promotes degradation of EGF receptor and inhibits downstream ERK signaling. We also found that PTPD1 is markedly increased in bladder cancer tissue samples. PTPD1 levels positively correlated with the grading and invasiveness potential of these tumors. Transgenic expression of an inactive PTPD1 mutant or genetic knockdown of the endogenous PTPD1 severely inhibited both growth and motility of human bladder cancer cells. These findings identify PTPD1 as a novel component of the endocytic machinery that impacts on EGF receptor stability and on growth and motility of bladder cancer cells.

Collaboration


Dive into the Massimo Mascolo's collaboration.

Top Co-Authors

Avatar

Stefania Staibano

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar

Gennaro Ilardi

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar

Gaetano De Rosa

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar

Daniela Russo

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar

Francesco Merolla

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar

Maria Siano

University of Naples Federico II

View shared research outputs
Top Co-Authors

Avatar

S. Staibano

Seconda Università degli Studi di Napoli

View shared research outputs
Top Co-Authors

Avatar

Vincenzo Piccolo

Seconda Università degli Studi di Napoli

View shared research outputs
Top Co-Authors

Avatar

Giuseppe Argenziano

Seconda Università degli Studi di Napoli

View shared research outputs
Top Co-Authors

Avatar

Massimiliano Scalvenzi

University of Naples Federico II

View shared research outputs
Researchain Logo
Decentralizing Knowledge